Suppr超能文献

从伦理问题到医疗法律层面看新冠疫苗的超说明书使用:意大利视角

Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian Perspective.

作者信息

Ferorelli Davide, Spagnolo Lorenzo, Marrone Maricla, Corradi Serena, Silvestre Maria, Misceo Federica, Bianchi Francesco Paolo, Stefanizzi Pasquale, Solarino Biagio, Dell'Erba Alessandro, Tafuri Silvio

机构信息

Section of Legal Medicine, Interdisciplinary Department of Medicine, University of Bari, 70121 Bari, Italy.

Department of Biomedical Sciences and Human Oncology, Aldo Moro University of Bari, 70121 Bari, Italy.

出版信息

Vaccines (Basel). 2021 Apr 23;9(5):423. doi: 10.3390/vaccines9050423.

Abstract

During the COVID-19 outbreak, the lack of official recommendations on the treatment has led healthcare workers to use multiple drugs not specifically tested and approved for the new insidious disease. After the availability of the first COVID-19 vaccines (Comirnaty Pfizer-BioNTech and Moderna COVID19 vaccine), an authorization was issued by national and international Drug Regulatory Agencies in order to speed up their introduction on the market and their administration on a large scale. Despite the authorization, the off-label use of these vaccines may still be possible especially to answer specific concerns as the lack of vaccine doses, the delay in the delivery of planned doses or the pressure from public opinion and political influence also in relation to the evolution of the pandemic. This paper aims to assess the possible off-label use of COVID-19 vaccines and the ethical and medico-legal implications of this eventuality. The scope of this paper is to point out the possible consequences of off-label use of COVID-19 vaccines and possible mitigation and preventive measures to be taken by healthcare workers involved in vaccination procedures.

摘要

在新冠疫情爆发期间,由于缺乏关于治疗的官方建议,医护人员不得不使用多种未经专门针对这种新型隐匿性疾病进行测试和批准的药物。在首批新冠疫苗(辉瑞 - 生物科技公司的Comirnaty和莫德纳新冠疫苗)上市后,国家和国际药品监管机构发布了授权,以加快其上市和大规模接种。尽管有了授权,但这些疫苗的超说明书使用仍有可能,特别是为了应对一些具体问题,比如疫苗剂量短缺、计划剂量交付延迟,或者在疫情发展过程中来自公众舆论和政治影响的压力。本文旨在评估新冠疫苗可能的超说明书使用情况以及这种可能性所带来的伦理和医学法律影响。本文的范围是指出新冠疫苗超说明书使用可能产生的后果,以及参与疫苗接种程序的医护人员应采取的可能的缓解和预防措施。

相似文献

5
[Current state of vaccination against SARS-CoV-2].[新型冠状病毒2型(SARS-CoV-2)疫苗接种的现状]
Z Rheumatol. 2021 Mar;80(2):158-164. doi: 10.1007/s00393-021-00966-9. Epub 2021 Feb 2.
10
COVID-19 vaccination in India: An ethical perspective.印度的 COVID-19 疫苗接种:伦理视角。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102314. doi: 10.1016/j.dsx.2021.102314. Epub 2021 Oct 15.

本文引用的文献

5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
Off-label use of vaccines.疫苗的非标签使用。
Vaccine. 2017 Apr 25;35(18):2329-2337. doi: 10.1016/j.vaccine.2017.02.056. Epub 2017 Mar 22.
10
Off-label drug use in oncology: a systematic review of literature.肿瘤学中的药物非标签使用:文献系统综述
J Clin Pharm Ther. 2017 Jun;42(3):251-258. doi: 10.1111/jcpt.12507. Epub 2017 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验